Business Strategy Solvay to Advance Bio-based Innovations by Investing in DMC Biotechnologies

By investing in DMC Biotechnologies, Solvay Ventures has made the company its first portfolio company in biotechnology. The biotech firm offers robust and predictably scalable biocatalysts through microbial fermentation which leads to the production of cost-competitive bio-based chemicals for numerous applications.

Related Vendors

Glatt Ingenieurtechnik GmbH

Pörner Ingenieurgesellschaft mbH

TRM Filter d.o.o.

Solvay SA - Corporate Headquarters

Brussels/Belgium – Solvay Ventures, the venture capital fund of Solvay, has invested in DMC Biotechnologies, a U.S.-based biotechnology company. DMC, which stands for Dynamic Metabolic Control, delivers robust and predictably scalable biocatalysts through microbial fermentation. This results in cost-competitive bio-based chemicals produced for animal feed, human nutrition, sustainable cleaning and pharmaceutical applications.

DMC represents Solvay Venture's first portfolio company in biotechnology. Its core technology addresses a key challenge for biotech companies, considered to be the next wave of a biotechnology paradigm, as it decouples cell growth and production while optimizing metabolic pathways in each phase. This optimization results in unprecedented yields and predictability for scale-up.

“DMC has demonstrated exceptional speed by moving from targeted molecules to products ready for commercialization at the right scale. The versatility of the platform, translated into the large range of products, aligns perfectly with Solvay's aspiration to bring more bio-based solutions to market,” says Thomas Canova, Head of Solvay Ventures.

(ID:47876164)